Paris, France and Camberley, UK – 18 June 2021 – Novacyt S.A. (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it will report its audited
Novacyt S.A. (NCYT.L) DHSC Dispute Update
Paris, France and Camberley, UK – 21 May 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update to its ongoing dispute with
Novacyt S.A. (NCYT.L) Inclusion of SNPsig in the NHS England Framework
Inclusion of SNPsig® SARS-CoV-2 PCR genotyping portfolio in the NHS England Framework and expansion of SNPsig® product range
Novacyt S.A. (NCYT.L) Novacyt donates 1 million COVID-19 tests to UNICEF
Donation supports testing efforts to help ensure continued access to essential services for children and their families
Novacyt S.A. (NCYT.L) R&D and UK operational update
Paris, France and Camberley, UK – 23 April 2021 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics.
Novacyt S.A. (NCYT.L) Trading Update
Paris, France and Camberley, UK – 9 April 2021 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces an update on its supply contract with
Novacyt S.A. (NCYT.L) Full Year 2020 Trading Update
Paris, France and Camberley, UK – 29 January 2021 – Novacyt ( EURONEXT GROWTH: ALNOV; AIM: NCYT ), an international specialist in clinical diagnostics, announces an unaudited trading update for
Novacyt S.A. (NCYT.L) Director/PDMR Shareholding
Paris, France and Camberley, UK – 12 November 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces that it has been notified that, on
Novacyt S.A. (NCYT.L) Liquidity Agreement and Total Voting Rights
Paris, France and Camberley, UK – 2 November 2020 – Novacyt (EURONEXT GROWTH: ALNOV; AIM: NCYT), an international specialist in clinical diagnostics, announces its monthly update in relation to ordinary
Novacyt S.A. (NCYT.L) Acquisition of IT-IS International Ltd
Deal in line with strategy, secures key IP for the Company’s rapid-PCR instruments, expands its core capabilities and product offering